- Home
- NGVC vs MLYS Comparison
NGVC vs MLYS Comparison
Compare NGVC & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGVC
- MLYS
- Stock Information
- Founded
- NGVC 1955
- MLYS 2019
- Country
- NGVC United States
- MLYS United States
- Employees
- NGVC N/A
- MLYS N/A
- Industry
- NGVC Food Chains
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- NGVC Consumer Staples
- MLYS Health Care
- Exchange
- NGVC Nasdaq
- MLYS Nasdaq
- Market Cap
- NGVC 1.1B
- MLYS 893.0M
- IPO Year
- NGVC 2012
- MLYS 2023
- Fundamental
- Price
- NGVC $59.82
- MLYS $14.65
- Analyst Decision
- NGVC
- MLYS Strong Buy
- Analyst Count
- NGVC 0
- MLYS 3
- Target Price
- NGVC N/A
- MLYS $33.00
- AVG Volume (30 Days)
- NGVC 176.6K
- MLYS 650.3K
- Earning Date
- NGVC 05-08-2025
- MLYS 05-12-2025
- Dividend Yield
- NGVC 0.79%
- MLYS N/A
- EPS Growth
- NGVC 42.37
- MLYS N/A
- EPS
- NGVC 1.78
- MLYS N/A
- Revenue
- NGVC $1,297,733,000.00
- MLYS N/A
- Revenue This Year
- NGVC $1.32
- MLYS N/A
- Revenue Next Year
- NGVC N/A
- MLYS N/A
- P/E Ratio
- NGVC $25.77
- MLYS N/A
- Revenue Growth
- NGVC 9.36
- MLYS N/A
- 52 Week Low
- NGVC $17.65
- MLYS $8.24
- 52 Week High
- NGVC $52.69
- MLYS $18.38
- Technical
- Relative Strength Index (RSI)
- NGVC 75.41
- MLYS 53.36
- Support Level
- NGVC $45.67
- MLYS $14.03
- Resistance Level
- NGVC $52.69
- MLYS $15.79
- Average True Range (ATR)
- NGVC 2.68
- MLYS 0.99
- MACD
- NGVC 0.32
- MLYS 0.10
- Stochastic Oscillator
- NGVC 93.27
- MLYS 57.57
About NGVC Natural Grocers by Vitamin Cottage Inc.
Natural Grocers by Vitamin Cottage Inc operates natural and organic grocery and dietary supplement stores. It offers the following product categories, natural and organic food, dietary supplements, natural body care, household, pet care products, books and handouts. The Company has a single reporting segment, natural and organic retail stores, through which business are conducted. The company generates the majority of its revenue from grocery products and dietary supplements and rest from other products.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.